Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 372 entries
Sorted by: Best Match Show Resources per page
Nematode Peptides with Host-Directed Anti-inflammatory Activity Rescue Caenorhabditis elegans from a Burkholderia pseudomallei Infection.

Frontiers in microbiology

Lim MP, Firdaus-Raih M, Nathan S.
PMID: 27672387
Front Microbiol. 2016 Sep 12;7:1436. doi: 10.3389/fmicb.2016.01436. eCollection 2016.

Burkholderia pseudomallei, the causative agent of melioidosis, is among a growing number of bacterial pathogens that are increasingly antibiotic resistant. Antimicrobial peptides (AMPs) have been investigated as an alternative approach to treat microbial infections, as generally, there is a...

Cite
Lim MP, Firdaus-Raih M, Nathan S. Nematode Peptides with Host-Directed Anti-inflammatory Activity Rescue Caenorhabditis elegans from a Burkholderia pseudomallei Infection. Front Microbiol. 2016;7:1436doi: 10.3389/fmicb.2016.01436.
Lim, M. P., Firdaus-Raih, M., & Nathan, S. (2016). Nematode Peptides with Host-Directed Anti-inflammatory Activity Rescue Caenorhabditis elegans from a Burkholderia pseudomallei Infection. Frontiers in microbiology, 71436. https://doi.org/10.3389/fmicb.2016.01436
Lim, Mei-Perng, et al. "Nematode Peptides with Host-Directed Anti-inflammatory Activity Rescue Caenorhabditis elegans from a Burkholderia pseudomallei Infection." Frontiers in microbiology vol. 7 (2016): 1436. doi: https://doi.org/10.3389/fmicb.2016.01436
Lim MP, Firdaus-Raih M, Nathan S. Nematode Peptides with Host-Directed Anti-inflammatory Activity Rescue Caenorhabditis elegans from a Burkholderia pseudomallei Infection. Front Microbiol. 2016 Sep 12;7:1436. doi: 10.3389/fmicb.2016.01436. eCollection 2016. PMID: 27672387; PMCID: PMC5019075.
Copy Download .nbib Format: NLM
Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa.

Journal of the International AIDS Society

Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP.
PMID: 27677395
J Int AIDS Soc. 2016 Sep 26;19(1):20987. doi: 10.7448/IAS.19.1.20987. eCollection 2016.

INTRODUCTION: A substantial number of patients with HIV in South Africa have failed first-line antiretroviral therapy (ART). Although individual predictors of first-line ART failure have been identified, few studies in resource-limited settings have been large enough for predictive modelling....

Cite
Rohr JK, Ive P, Horsburgh CR, et al. Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. J Int AIDS Soc. 2016;19(1):20987doi: 10.7448/IAS.19.1.20987.
Rohr, J. K., Ive, P., Horsburgh, C. R., Berhanu, R., Shearer, K., Maskew, M., Long, L., Sanne, I., Bassett, J., Ebrahim, O., & Fox, M. P. (2016). Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. Journal of the International AIDS Society, 19(1), 20987. https://doi.org/10.7448/IAS.19.1.20987
Rohr, Julia K, et al. "Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa." Journal of the International AIDS Society vol. 19,1 (2016): 20987. doi: https://doi.org/10.7448/IAS.19.1.20987
Rohr JK, Ive P, Horsburgh CR, Berhanu R, Shearer K, Maskew M, Long L, Sanne I, Bassett J, Ebrahim O, Fox MP. Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa. J Int AIDS Soc. 2016 Sep 26;19(1):20987. doi: 10.7448/IAS.19.1.20987. eCollection 2016. PMID: 27677395; PMCID: PMC5039239.
Copy Download .nbib Format: NLM
Exploring Healthcare Experiences of Transgender Individuals.

Transgender health

Ross KAE, Law MP, Bell A.
PMID: 28861538
Transgend Health. 2016 Nov 01;1(1):238-249. doi: 10.1089/trgh.2016.0021. eCollection 2016.

No abstract available.

Cite
Ross KAE, Law MP, Bell A. Exploring Healthcare Experiences of Transgender Individuals. Transgend Health. 2016;1(1):238-249doi: 10.1089/trgh.2016.0021.
Ross, K. A. E., Law, M. P., & Bell, A. (2016). Exploring Healthcare Experiences of Transgender Individuals. Transgender health, 1(1), 238-249. https://doi.org/10.1089/trgh.2016.0021
Ross, Katie A E, et al. "Exploring Healthcare Experiences of Transgender Individuals." Transgender health vol. 1,1 (2016): 238-249. doi: https://doi.org/10.1089/trgh.2016.0021
Ross KAE, Law MP, Bell A. Exploring Healthcare Experiences of Transgender Individuals. Transgend Health. 2016 Nov 01;1(1):238-249. doi: 10.1089/trgh.2016.0021. eCollection 2016. PMID: 28861538; PMCID: PMC5367478.
Copy Download .nbib Format: NLM
Thermoelectric Properties of Ag-Doped Bi2(Se,Te)3 Compounds: Dual Electronic Nature of Ag-Related Lattice Defects.

Inorganic chemistry

Lu MP, Liao CN, Huang JY, Hsu HC.
PMID: 26200130
Inorg Chem. 2015 Aug 03;54(15):7438-44. doi: 10.1021/acs.inorgchem.5b01031. Epub 2015 Jul 22.

Effects of Ag doping and thermal annealing temperature on thermoelectric transport properties of Bi2(Se,Te)3 compounds are investigated. On the basis of the comprehensive analysis of carrier concentration, Hall mobility, and lattice parameter, we identified two Ag-related interstitial (Agi) and...

Cite
Lu MP, Liao CN, Huang JY, et al. Thermoelectric Properties of Ag-Doped Bi2(Se,Te)3 Compounds: Dual Electronic Nature of Ag-Related Lattice Defects. Inorg Chem. 2015;54(15):7438-44doi: 10.1021/acs.inorgchem.5b01031.
Lu, M. P., Liao, C. N., Huang, J. Y., & Hsu, H. C. (2015). Thermoelectric Properties of Ag-Doped Bi2(Se,Te)3 Compounds: Dual Electronic Nature of Ag-Related Lattice Defects. Inorganic chemistry, 54(15), 7438-44. https://doi.org/10.1021/acs.inorgchem.5b01031
Lu, Meng-Pei, et al. "Thermoelectric Properties of Ag-Doped Bi2(Se,Te)3 Compounds: Dual Electronic Nature of Ag-Related Lattice Defects." Inorganic chemistry vol. 54,15 (2015): 7438-44. doi: https://doi.org/10.1021/acs.inorgchem.5b01031
Lu MP, Liao CN, Huang JY, Hsu HC. Thermoelectric Properties of Ag-Doped Bi2(Se,Te)3 Compounds: Dual Electronic Nature of Ag-Related Lattice Defects. Inorg Chem. 2015 Aug 03;54(15):7438-44. doi: 10.1021/acs.inorgchem.5b01031. Epub 2015 Jul 22. PMID: 26200130.
Copy Download .nbib Format: NLM
RAS pathway biomarkers for breast cancer prognosis.

Clinical laboratory international

Siewertsz van Reesema LL, Lee MP, Zheleva V, Winston JS, O'Connor CF, Perry RR, Hoefer RA, Tang AH.
PMID: 28579913
Clin Lab Int. 2016 Nov;40:18-23.

Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer...

Cite
Siewertsz van Reesema LL, Lee MP, Zheleva V, et al. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016;40:18-23
Siewertsz van Reesema, L. L., Lee, M. P., Zheleva, V., Winston, J. S., O'Connor, C. F., Perry, R. R., Hoefer, R. A., & Tang, A. H. (2016). RAS pathway biomarkers for breast cancer prognosis. Clinical laboratory international, 4018-23.
Siewertsz van Reesema, Lauren L, et al. "RAS pathway biomarkers for breast cancer prognosis." Clinical laboratory international vol. 40 (2016): 18-23.
Siewertsz van Reesema LL, Lee MP, Zheleva V, Winston JS, O'Connor CF, Perry RR, Hoefer RA, Tang AH. RAS pathway biomarkers for breast cancer prognosis. Clin Lab Int. 2016 Nov;40:18-23. PMID: 28579913; PMCID: PMC5455995.
Copy Download .nbib Format: NLM
Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.

Oncotarget

Tayyari F, Gowda GAN, Olopade OF, Berg R, Yang HH, Lee MP, Ngwa WF, Mittal SK, Raftery D, Mohammed SI.
PMID: 29545929
Oncotarget. 2018 Feb 07;9(14):11677-11690. doi: 10.18632/oncotarget.24433. eCollection 2018 Feb 20.

Breast cancer, a heterogeneous disease with variable pathophysiology and biology, is classified into four major subtypes. While hormonal- and antibody-targeted therapies are effective in the patients with luminal and HER-2 subtypes, the patients with triple-negative breast cancer (TNBC) subtype...

Cite
Tayyari F, Gowda GAN, Olopade OF, et al. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget. 2018;9(14):11677-11690doi: 10.18632/oncotarget.24433.
Tayyari, F., Gowda, G. A. N., Olopade, O. F., Berg, R., Yang, H. H., Lee, M. P., Ngwa, W. F., Mittal, S. K., Raftery, D., & Mohammed, S. I. (2018). Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget, 9(14), 11677-11690. https://doi.org/10.18632/oncotarget.24433
Tayyari, Fariba, et al. "Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences." Oncotarget vol. 9,14 (2018): 11677-11690. doi: https://doi.org/10.18632/oncotarget.24433
Tayyari F, Gowda GAN, Olopade OF, Berg R, Yang HH, Lee MP, Ngwa WF, Mittal SK, Raftery D, Mohammed SI. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget. 2018 Feb 07;9(14):11677-11690. doi: 10.18632/oncotarget.24433. eCollection 2018 Feb 20. PMID: 29545929; PMCID: PMC5837744.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Geburtshilfe und Frauenheilkunde

Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
PMID: 29576630
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes...

Cite
Schneeweiss A, Lux MP, Janni W, et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018;78(3):246-259doi: 10.1055/s-0044-101614.
Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F. A., Overkamp, F., Kolberg, H. C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., Schütz, F., Fasching, P. A., & Fehm, T. N. (2018). Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe und Frauenheilkunde, 78(3), 246-259. https://doi.org/10.1055/s-0044-101614
Schneeweiss, Andreas, et al. "Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention." Geburtshilfe und Frauenheilkunde vol. 78,3 (2018): 246-259. doi: https://doi.org/10.1055/s-0044-101614
Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21. PMID: 29576630; PMCID: PMC5862553.
Copy Download .nbib Format: NLM
Development of a 3D printer using scanning projection stereolithography.

Scientific reports

Lee MP, Cooper GJ, Hinkley T, Gibson GM, Padgett MJ, Cronin L.
PMID: 25906401
Sci Rep. 2015 Apr 23;5:9875. doi: 10.1038/srep09875.

We have developed a system for the rapid fabrication of low cost 3D devices and systems in the laboratory with micro-scale features yet cm-scale objects. Our system is inspired by maskless lithography, where a digital micromirror device (DMD) is...

Cite
Lee MP, Cooper GJ, Hinkley T, et al. Development of a 3D printer using scanning projection stereolithography. Sci Rep. 2015;5:9875doi: 10.1038/srep09875.
Lee, M. P., Cooper, G. J., Hinkley, T., Gibson, G. M., Padgett, M. J., & Cronin, L. (2015). Development of a 3D printer using scanning projection stereolithography. Scientific reports, 59875. https://doi.org/10.1038/srep09875
Lee, Michael P, et al. "Development of a 3D printer using scanning projection stereolithography." Scientific reports vol. 5 (2015): 9875. doi: https://doi.org/10.1038/srep09875
Lee MP, Cooper GJ, Hinkley T, Gibson GM, Padgett MJ, Cronin L. Development of a 3D printer using scanning projection stereolithography. Sci Rep. 2015 Apr 23;5:9875. doi: 10.1038/srep09875. PMID: 25906401; PMCID: PMC4407727.
Copy Download .nbib Format: NLM
Reconstruction and control of a time-dependent two-electron wave packet.

Nature

Ott C, Kaldun A, Argenti L, Raith P, Meyer K, Laux M, Zhang Y, Blättermann A, Hagstotz S, Ding T, Heck R, Madroñero J, Martín F, Pfeifer T.
PMID: 25519135
Nature. 2014 Dec 18;516(7531):374-8. doi: 10.1038/nature14026.

The concerted motion of two or more bound electrons governs atomic and molecular non-equilibrium processes including chemical reactions, and hence there is much interest in developing a detailed understanding of such electron dynamics in the quantum regime. However, there...

Cite
Ott C, Kaldun A, Argenti L, et al. Reconstruction and control of a time-dependent two-electron wave packet. Nature. 2014;516(7531):374-8doi: 10.1038/nature14026.
Ott, C., Kaldun, A., Argenti, L., Raith, P., Meyer, K., Laux, M., Zhang, Y., Blättermann, A., Hagstotz, S., Ding, T., Heck, R., Madroñero, J., Martín, F., & Pfeifer, T. (2014). Reconstruction and control of a time-dependent two-electron wave packet. Nature, 516(7531), 374-8. https://doi.org/10.1038/nature14026
Ott, Christian, et al. "Reconstruction and control of a time-dependent two-electron wave packet." Nature vol. 516,7531 (2014): 374-8. doi: https://doi.org/10.1038/nature14026
Ott C, Kaldun A, Argenti L, Raith P, Meyer K, Laux M, Zhang Y, Blättermann A, Hagstotz S, Ding T, Heck R, Madroñero J, Martín F, Pfeifer T. Reconstruction and control of a time-dependent two-electron wave packet. Nature. 2014 Dec 18;516(7531):374-8. doi: 10.1038/nature14026. PMID: 25519135.
Copy Download .nbib Format: NLM
Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se.

Geburtshilfe und Frauenheilkunde

Schulz-Wendtland R, Bani M, Lux MP, Schwab S, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Fasching PA, Adamietz B, Meier-Meitinger M.
PMID: 25298545
Geburtshilfe Frauenheilkd. 2012 May;72(5):408-411. doi: 10.1055/s-0031-1298158.

No abstract available.

Cite
Schulz-Wendtland R, Bani M, Lux MP, et al. Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se. Geburtshilfe Frauenheilkd. 2012;72(5):408-411doi: 10.1055/s-0031-1298158.
Schulz-Wendtland, R., Bani, M., Lux, M. P., Schwab, S., Loehberg, C. R., Jud, S. M., Rauh, C., Bayer, C. M., Beckmann, M. W., Uder, M., Fasching, P. A., Adamietz, B., & Meier-Meitinger, M. (2012). Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se. Geburtshilfe und Frauenheilkunde, 72(5), 408-411. https://doi.org/10.1055/s-0031-1298158
Schulz-Wendtland, R, et al. "Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se." Geburtshilfe und Frauenheilkunde vol. 72,5 (2012): 408-411. doi: https://doi.org/10.1055/s-0031-1298158
Schulz-Wendtland R, Bani M, Lux MP, Schwab S, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Fasching PA, Adamietz B, Meier-Meitinger M. Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se. Geburtshilfe Frauenheilkd. 2012 May;72(5):408-411. doi: 10.1055/s-0031-1298158. PMID: 25298545; PMCID: PMC4168403.
Copy Download .nbib Format: NLM
Significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesion.

World journal of gastroenterology

Wu JF, Song YL, Yang GL, Dong YM, Wang DB, Liu MP.
PMID: 27239132
World J Gastroenterol. 1997 Sep 15;3(3):159. doi: 10.3748/wjg.v3.i3.159.

AIM: To study the significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesions.METHODS: Immunohistochemical staining and mucin histochemical staining were performed on paraffin-embedded sections from gastric benign and malignant lesions from 101 patients.RESULTS: SC3A positive rate...

Cite
Wu JF, Song YL, Yang GL, et al. Significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesion. World J Gastroenterol. 1997;3(3):159doi: 10.3748/wjg.v3.i3.159.
Wu, J. F., Song, Y. L., Yang, G. L., Dong, Y. M., Wang, D. B., & Liu, M. P. (1997). Significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesion. World journal of gastroenterology, 3(3), 159. https://doi.org/10.3748/wjg.v3.i3.159
Wu, J F, et al. "Significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesion." World journal of gastroenterology vol. 3,3 (1997): 159. doi: https://doi.org/10.3748/wjg.v3.i3.159
Wu JF, Song YL, Yang GL, Dong YM, Wang DB, Liu MP. Significance of monoclonal antibody SC3A expression in gastric carcinoma and precancerous lesion. World J Gastroenterol. 1997 Sep 15;3(3):159. doi: 10.3748/wjg.v3.i3.159. PMID: 27239132; PMCID: PMC4842873.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 372 entries